OncLive TV

Gilberto De Lima Lopes, MD, discusses the rationale to stop immunotherapy after 2 years in patients with lung cancer.

Adam M. Brufsky, MD, PhD, discusses the risk the coronavirus disease 2019 poses to patients with cancer.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Vivek Subbiah, MD, discusses the utility of tivozanib in renal cell carcinoma.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Preetesh Jain, MD, PhD, discusses response and resistance to venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Alan H. Bryce, MD, discusses the accelerated approval of rucaparib (Rubraca) for the treatment of adult patients with BRCA mutation (germline and/or somatic)–associated metastatic castration-resistant prostate cancer (mCRPC) who have been treated with androgen receptor–directed therapy and a taxane-based chemotherapy.

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.

Lyudmila A. Bazhenova, MD, discusses the PACIFIC study with durvalumab in stage III non–small-cell lung cancer.

Eric A. Klein, MD, discusses the importance of providing genomic testing to patients with prostate cancer.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Nizar J. Bahlis, MD, discusses updated data from the phase 3 MAIA trial in multiple myeloma.

Adilia Hormigo, MD, PhD, discusses the impact of the coronavirus disease 2019 (COVID-19) on high density areas.

Van K. Morris, MD, discusses the role of immunotherapy in metastatic colorectal cancer.

Luis E. Raez, MD, discusses the safety measures that have been put in place at Memorial Cancer Institute in response to the coronavirus disease 2019 (COVID-19) in lung cancer.

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

Mark A. Schroeder, MD, discusses the importance of JAK inhibition in graft-versus-host disease (GVHD).

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

David P. Carbone, MD, PhD, discusses the impact of immunotherapy on lung cancer.

Hope S. Rugo, MD, discusses recent updates with immunotherapy in triple negative breast cancer.

Panayiotis S. Savvides, MD, discusses the utility of immunotherapy in lung cancer.

Jennifer Litton, MD, discusses the findings from the overall survival analysis of the EMBRACA trial, the implications of these data, and the future utility of talazoparib in this space.

Sonali M. Smith, MD, discusses ongoing research in relapsed/refractory mantle cell lymphoma.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.

Manish Kohli, MD, discusses the use of enzalutamide (Xtandi) and apalutamide (Erleada) in patients with metastatic hormone-sensitive prostate cancer (mHSPC).

Manoj K. Jain, MD, discusses diagnostic tracers in prostate cancer.

Anastasios (Tassos) Dimou, MD, discusses emerging treatment options in BRAF-positive lung cancer.